• Vitamin K2 Matrix Products from Gnosis

    What is Matrix Technology?

    Matrix is a novel protective technology developed to ensure K2 stability in complex formulations in creative delivery formats. Gnosis state that “Stability data show Matrix protects the vitamin K2 molecule in very harsh conditions. 6 months in Accelerated conditions being equivalent to 24 months in ambient conditions.” Matrix technology features:

    • Clean label, no coating, no additive
    • Eases complex formulations
    • Proprietary technology

    New MenaQ7® Vitamin K2 Matrix

    This premium brand is scientifically supported and spotlights the following features:

    ENHANCED STABILITY
    The latest in vitamin K2 protection in complex formulations including minerals
    TRUE CLEAN LABEL
    Natural protection with a short list of ingredients and no additives
    DISPERSIBILITY
    Made to disperse easily in liquids (i.e. sports powders, milk powders, sachets)
    COST-EFFECTIVE MANUFACTURING

    Improved stability and homogeneity reduces the need for overage

    With the clinically proven* bone and cardiovascular health benefits of MenaQ7® as the foundation, Gnosis by Lesaffre is raising its premium Vitamin K2 brand to new heights.

    Download the MenaQ7® brochure

    vitaMK7® The new generation vitamin K2 in powder form

    vitaMK7® is the optimal vitamin K2 from natural biotransformation:
    a naturally derived, allergen-free vitamin K2 in the form of MK-7, produced by Gnosis by Lesaffre in its own European manufacturing site through a patented biofermentation process of Bacillus subtilis natto.

    Download the vitaMK7® brochure

    *MenaQ7® Research

    MenaQ7® and Cardiovascular Health

    Vermeer C and Vik H. Vascular Diseases and Therapeutics. 2020
    Mansour et al. Journal of the American Society of Hypertension. 2017
    Aoun et al. BMC Nephrology. 2017
    Knapen et al. European Journal of Clinical Nutrition. 2016
    Knapen et al. Journal of Nutritional Science. 2015
    Kurnatowska et al. Polish Archives of Internal Medicine. 2015
    Knapen et al. Thrombosis and Haemostasis. 2015
    Theuwissen et al. British Journal of Nutrition. 2012
    Chatrou et al. Blood Review. 2012
    Dalmeijer et al. Atherosclerosis. 2012

    MenaQ7® and Bone Health

    Knapen et al. Osteoporosis International. 2013
    Ozdemir et al. Journal Pediatric Hematology Oncology. 2013
    van Summeren et al. British Journal of Nutrition. 2009

    MenaQ7® in Diseased Populations

    Mansour et al. Journal of the American Society of Hypertension. 2017
    Aoun et al. BMC Nephrology. 2017
    Kurnatowska et al. Polish Archive of Internal Medicine, 2015
    Calwue et al. Nephrology Dialysis Transplant. 2014
    Ozdemir et al. Journal Pediatric Hematology Oncology. 2013
    Westenfeld et al. American Journal of Kidney Disease. 2012

    MenaQ7® in Healthy Populations and Children’s Health

    Theuwissen et al. Food & Function. 2014
    van Summeren et al. British Journal of Nutrition. 2009

    MenaQ7® for Optimal Bioavailability

    Sato et al. Nutrition Journal. 2012
    Schurgers et al. Blood. 2007



    Please get in touch if you want more information or have questions about our ingredients

    This image has an empty alt attribute; its file name is Get-in-touch-button-1.png